Expert Speaks on Application of Integrative Kidney Cancer Care

Video

According to an expert from University Hospitals, oncologists should work together and look for opportunities to improve patients’ diets and exercise routines to mitigate symptoms of kidney cancer and associated treatment.

It is important to think of how integrative oncology can be applied to different scenarios in kidney cancer, including positive lifestyle changes and symptom management, according to Santosh Rao, MD.

Rao, medical director of integrative oncology for University Hospitals Connor Whole Health and president-elect for the Society for Integrative Oncology, spoke with CancerNetwork® during Kidney Cancer Awareness Month 2023as to how the benefit of integrative oncology can be fully harnessed.

Additionally, Rao suggested tapping into guidelines such as the National Comprehensive Cancer Network (NCCN) to assess what integrative medicine options are available for every practice including acupuncture and yoga, which may help patients mange disease symptoms and adverse effects based on available evidence.

Transcript:

I would hope that my colleagues think about integrative oncology and specifically [how] we can use it in different scenarios. What I tell my colleagues is if you have somebody who has pain, neuropathy, and fatigue, look up the NCCN guidelines and think about if you have certain [options] available in your own institution and your clinical practice.Acupuncture and yoga are very well represented in the NCCN guidelines, as well as some of the guidelines that I’ve already spoken about. [We should] think about that because if it’s available and [they are] low risk, you might really help your patients.

[We should also] think of opportunities to reduce stress and improve our patients] diet and exercise. That may look different in different places, but developing a team approach has been really helpful. [Think of] ways to involve the right people at the right time in multidisciplinary care. My sense is that if you have a team approach, you involve the right people at the right time, there’s good communication, and it’s patient-centered, you could potentially help somebody when they need it the most. That’s the direction we want to head in.

Recent Videos
Shwetal Mehta, PhD, describes efforts regarding the development of protein degraders and antibody-drug conjugates in the neuro-oncology field.
Liquid biopsy tests may help determine the extent of activity among patients who receive a novel fourth-generation EGFR inhibitor for brain cancer.
Shwetal Mehta, PhD, highlights novel brain cancer drug development procedures in the clinical lab and pre-clinical arms of the Ivy Brain Tumor Center.
Observing changes in the tumor microenvironment before and after a biopsy may elucidate how kidney cancer cells interact with immune cells.
Various kidney cancer trials have combined agents such as A2a receptor inhibitors with immunotherapy backbones to potentially improve treatment outcomes.
Leveraging novel agents, innovative clinical trial designs, and correlative studies may improve the treatment of patients with kidney cancer.
Sympathomimetic effects related to psilocybin may preclude use among patients with coronary artery disease or those with a high risk of stroke.
Psilocybin-assisted psychotherapy may be integrated into pre-existing behavioral health aspects of comprehensive cancer treatment.
Psilocybin may help address a need for effective medication to aid those who have psychological challenges related to a serious cancer diagnosis.
Related Content